Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSIW) Receivables (2022 - 2025)

TriSalus Life Sciences' Receivables history spans 4 years, with the latest figure at $6.6 million for Q4 2025.

  • For Q4 2025, Receivables rose 29.74% year-over-year to $6.6 million; the TTM value through Dec 2025 reached $6.6 million, up 29.74%, while the annual FY2025 figure was $6.6 million, 29.74% up from the prior year.
  • Receivables reached $6.6 million in Q4 2025 per TLSIW's latest filing, up from $5.0 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $6.6 million in Q4 2025 to a low of $1.6 million in Q4 2022.
  • Average Receivables over 4 years is $4.5 million, with a median of $4.9 million recorded in 2024.
  • Peak YoY movement for Receivables: surged 128.26% in 2023, then rose 1.79% in 2025.
  • A 4-year view of Receivables shows it stood at $1.6 million in 2022, then soared by 128.26% to $3.6 million in 2023, then skyrocketed by 43.13% to $5.1 million in 2024, then increased by 29.74% to $6.6 million in 2025.
  • Per Business Quant, the three most recent readings for TLSIW's Receivables are $6.6 million (Q4 2025), $5.0 million (Q3 2025), and $5.6 million (Q2 2025).